CO2023014204A2 - Inhibidores de la cinasa relacionada con el gen nunca en mitosis a 7 (nek7) - Google Patents
Inhibidores de la cinasa relacionada con el gen nunca en mitosis a 7 (nek7)Info
- Publication number
- CO2023014204A2 CO2023014204A2 CONC2023/0014204A CO2023014204A CO2023014204A2 CO 2023014204 A2 CO2023014204 A2 CO 2023014204A2 CO 2023014204 A CO2023014204 A CO 2023014204A CO 2023014204 A2 CO2023014204 A2 CO 2023014204A2
- Authority
- CO
- Colombia
- Prior art keywords
- nek7
- inhibitors
- never
- compounds
- related kinase
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 108091000080 Phosphotransferase Proteins 0.000 title 1
- 230000011278 mitosis Effects 0.000 title 1
- 102000020233 phosphotransferase Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 101000588545 Homo sapiens Serine/threonine-protein kinase Nek7 Proteins 0.000 abstract 1
- 108091008099 NLRP3 inflammasome Proteins 0.000 abstract 1
- 102100031400 Serine/threonine-protein kinase Nek7 Human genes 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163170708P | 2021-04-05 | 2021-04-05 | |
| US202163185282P | 2021-05-06 | 2021-05-06 | |
| PCT/US2022/023443 WO2022216680A1 (en) | 2021-04-05 | 2022-04-05 | Nek7 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2023014204A2 true CO2023014204A2 (es) | 2023-11-10 |
Family
ID=81448482
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2023/0014204A CO2023014204A2 (es) | 2021-04-05 | 2023-10-24 | Inhibidores de la cinasa relacionada con el gen nunca en mitosis a 7 (nek7) |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240317758A1 (https=) |
| EP (1) | EP4320127A1 (https=) |
| JP (1) | JP2024513227A (https=) |
| KR (1) | KR20230175222A (https=) |
| AU (1) | AU2022255486A1 (https=) |
| BR (1) | BR112023019435A2 (https=) |
| CA (1) | CA3214042A1 (https=) |
| CO (1) | CO2023014204A2 (https=) |
| IL (1) | IL307258A (https=) |
| MX (1) | MX2023011464A (https=) |
| PH (1) | PH12023552774A1 (https=) |
| WO (1) | WO2022216680A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS65962B1 (sr) | 2020-05-08 | 2024-10-31 | Halia Therapeutics Inc | Inhibitori nek7 kinaze |
| US20240158394A1 (en) * | 2022-09-14 | 2024-05-16 | Halia Therapeutics, Inc. | Nek7 inhibitors |
| IL322520A (en) * | 2023-02-24 | 2025-10-01 | Japan Tobacco Inc | Modified pyrazolopyrimidine compounds and their medical use |
| JP7729000B2 (ja) * | 2023-02-24 | 2025-08-25 | 日本たばこ産業株式会社 | ６－アルコキシピラゾロピリミジン化合物及びその医薬用途 |
| CN121368589A (zh) * | 2023-03-17 | 2026-01-20 | 万特斯治疗美国公司 | 用于抑制nlrp3的脲衍生物及其用途 |
| WO2025067411A1 (zh) * | 2023-09-28 | 2025-04-03 | 北京普祺医药科技股份有限公司 | 一种nek7抑制剂、药物组合物及其用途 |
| WO2025140570A1 (zh) * | 2023-12-29 | 2025-07-03 | 北京普祺医药科技股份有限公司 | 一种nek7抑制剂、药物组合物及其用途 |
| WO2026064385A1 (en) * | 2024-09-18 | 2026-03-26 | Ventus Therapeutics U.S., Inc. | Oxadiazolone inhibitors of nlrp3 and uses thereof |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
| US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| MXPA03008560A (es) | 2001-03-22 | 2004-06-30 | Abbot Gmbh & Co Kg | Pirazolopirimidinas como agentes terapeuticos. |
| WO2006066174A1 (en) | 2004-12-17 | 2006-06-22 | Eli Lilly And Company | Thiazolopyridinone derivates as mch receptor antagonists |
| KR20090064602A (ko) | 2006-10-16 | 2009-06-19 | 노파르티스 아게 | 단백질 키나제 억제제로서 유용한 페닐아세트아미드 |
| EP2170871A2 (en) | 2007-06-26 | 2010-04-07 | GlaxoSmithKline LLC | Processes for preparing benzimidazole thiophenes |
| WO2011047384A2 (en) * | 2009-10-16 | 2011-04-21 | The Regents Of The University Of California | Methods of inhibiting ire1 |
| UY33288A (es) | 2010-03-25 | 2011-10-31 | Glaxosmithkline Llc | Derivados de indolina inhibidores de la proteina quinasa r del reticulo endoplasmatico |
| TWI535712B (zh) | 2010-08-06 | 2016-06-01 | 阿斯特捷利康公司 | 化合物 |
| ES2658395T3 (es) | 2012-04-04 | 2018-03-09 | Rigel Pharmaceuticals, Inc. | Inhibidores de proteína cinasa C y usos de los mismos |
| CN103420977B (zh) | 2012-05-16 | 2016-06-22 | 上海医药集团股份有限公司 | 具有抗肿瘤活性的乙炔衍生物 |
| BR112014030284B1 (pt) | 2012-07-18 | 2021-11-30 | Sunshine Lake Pharma Co., Ltd | Composto, composição farmacêutica, e, uso de um composto ou de uma composição farmacêutica |
| US8859553B2 (en) | 2012-07-30 | 2014-10-14 | Astar Biotech Llc | Protein kinase inhibitors |
| ES2755772T3 (es) | 2012-11-07 | 2020-04-23 | Nerviano Medical Sciences Srl | Pirimidinil y piridinilpirrolopiridinonas sustituidas, proceso para su preparación y su uso como inhibidores de cinasas |
| EP2997030B1 (en) | 2013-05-14 | 2017-08-09 | Nerviano Medical Sciences S.R.L. | Pyrrolo[2,3-d]pyrimidine derivatives, process for their preparation and their use as kinase inhibitors |
| EA029412B1 (ru) | 2013-06-28 | 2018-03-30 | Бейджин, Лтд. | Конденсированные трициклические соединения мочевины в качестве ингибиторов киназы raf и/или димера киназы raf |
| WO2015117147A1 (en) | 2014-02-03 | 2015-08-06 | Quadriga Biosciences, Inc. | Beta-substituted beta-amino acids and analogs as chemotherapeutic agents |
| JP2017525727A (ja) | 2014-08-26 | 2017-09-07 | アスター バイオテック リミテッド ライアビリティ カンパニー | プロテインキナーゼ阻害剤 |
| CN105837575B (zh) | 2015-01-13 | 2019-01-15 | 四川大学 | 3-乙炔基吡唑并嘧啶衍生物及其制备方法和用途 |
| EA038421B1 (ru) | 2015-12-30 | 2021-08-26 | ВиПиЭс-3, ИНК. | Соединения, ингибирующие металлоферменты |
| CN107513068A (zh) | 2016-06-16 | 2017-12-26 | 中国科学院上海药物研究所 | 一种具有fgfr抑制活性的新型化合物及其制备和应用 |
| JP6570776B2 (ja) | 2016-06-20 | 2019-09-04 | テグ−キョンプク メディカル イノベーション ファウンデーション | 新規のイミダゾピリジン誘導体、その製造方法及びこれを有効成分として含有する癌の予防又は治療用医薬組成物 |
| JP6867417B2 (ja) | 2016-06-21 | 2021-04-28 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | キナーゼ阻害剤としてのｎ−（置換フェニル）−スルホンアミド誘導体 |
| EP3296297A1 (en) | 2016-09-15 | 2018-03-21 | Centre National De La Recherche Scientifique | Benzimidazol derivatives for treating filovirus infection |
| EP3548476A4 (en) | 2016-12-02 | 2020-05-20 | Quentis Therapeutics, Inc. | SMALL MOLECULAR IRE1 INHIBITORS |
| AU2018272986A1 (en) | 2017-05-26 | 2019-12-12 | Ichnos Sciences SA | Novel inhibitors of MAP4K1 |
| WO2018222917A1 (en) | 2017-06-01 | 2018-12-06 | Quentis Therapeutics, Inc. | Ire1 small molecule inhibitors |
| CA3074208C (en) | 2017-08-31 | 2023-10-03 | Daiichi Sankyo Company, Limited | Novel method for producing antibody-drug conjugate |
| IL277408B2 (en) * | 2018-04-05 | 2024-08-01 | Merck Patent Gmbh | Heteroaryl compounds as IRAK type II inhibitors and their use |
| WO2019196812A1 (zh) | 2018-04-09 | 2019-10-17 | 上海科技大学 | 蛋白降解靶向化合物、其抗肿瘤应用、其中间体及中间体应用 |
| US20210139484A1 (en) | 2018-04-11 | 2021-05-13 | Gossamer Bio Services, Inc. | Dihydroisoquinoline-2(1h)-carboxamide and related compounds and their use in treating medical conditions |
| CN112243439A (zh) | 2018-06-13 | 2021-01-19 | 百济神州有限公司 | 作为hpk1抑制剂的吡咯并[2,3-b]吡啶或吡咯并[2,3-b]吡嗪及其用途 |
| WO2020135507A1 (zh) | 2018-12-26 | 2020-07-02 | 杭州百新生物医药科技有限公司 | 一种多取代苯氨基嘧啶衍生物及其制备方法和用途 |
| CN111646995B (zh) * | 2019-03-04 | 2023-03-21 | 四川大学 | 4-氨基-嘧啶并氮杂环-苯基脲类衍生物及其制备方法和用途 |
| WO2020206583A1 (en) | 2019-04-08 | 2020-10-15 | Qilu Regor Therapeutics Inc. | Kinase inhibitors and uses thereof |
| CA3152508A1 (en) * | 2019-08-29 | 2021-03-04 | Hibercell, Inc. | Perk inhibiting pyrrolopyrimidine compounds |
| WO2021057877A1 (zh) * | 2019-09-26 | 2021-04-01 | 深圳市塔吉瑞生物医药有限公司 | 取代的芳香稠合环衍生物及其组合物及用途 |
| US20220389009A1 (en) | 2019-10-01 | 2022-12-08 | Goldfinch Bio, Inc. | Substituted 1,6-naphthyridine inhibitors of cdk5 |
| US12565481B2 (en) | 2020-02-20 | 2026-03-03 | Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. Baiyunshan Pharmaceutical General Factory | 6,7-dimethoxy-3-(pyridin-2-yl)quinoline compounds for inhibiting RET |
| WO2021226547A2 (en) | 2020-05-08 | 2021-11-11 | Halia Therapeutics, Inc. | Targeted nek7 inhibition for modulation of the nlrp3 inflammasome |
| CN113717156B (zh) | 2020-05-25 | 2023-05-09 | 南京红云生物科技有限公司 | Egfr抑制剂、其制备方法及用途 |
| GB202010464D0 (en) | 2020-07-08 | 2020-08-19 | Galapagos Nv | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases |
-
2022
- 2022-04-05 WO PCT/US2022/023443 patent/WO2022216680A1/en not_active Ceased
- 2022-04-05 US US18/553,828 patent/US20240317758A1/en active Pending
- 2022-04-05 KR KR1020237037931A patent/KR20230175222A/ko active Pending
- 2022-04-05 JP JP2023561240A patent/JP2024513227A/ja active Pending
- 2022-04-05 AU AU2022255486A patent/AU2022255486A1/en active Pending
- 2022-04-05 BR BR112023019435A patent/BR112023019435A2/pt unknown
- 2022-04-05 CA CA3214042A patent/CA3214042A1/en active Pending
- 2022-04-05 PH PH1/2023/552774A patent/PH12023552774A1/en unknown
- 2022-04-05 IL IL307258A patent/IL307258A/en unknown
- 2022-04-05 EP EP22720127.4A patent/EP4320127A1/en active Pending
- 2022-04-05 MX MX2023011464A patent/MX2023011464A/es unknown
-
2023
- 2023-10-24 CO CONC2023/0014204A patent/CO2023014204A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022255486A1 (en) | 2023-10-19 |
| KR20230175222A (ko) | 2023-12-29 |
| IL307258A (en) | 2023-11-01 |
| BR112023019435A2 (pt) | 2023-10-24 |
| JP2024513227A (ja) | 2024-03-22 |
| EP4320127A1 (en) | 2024-02-14 |
| CA3214042A1 (en) | 2022-10-13 |
| WO2022216680A1 (en) | 2022-10-13 |
| US20240317758A1 (en) | 2024-09-26 |
| MX2023011464A (es) | 2023-10-19 |
| PH12023552774A1 (en) | 2024-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2023014204A2 (es) | Inhibidores de la cinasa relacionada con el gen nunca en mitosis a 7 (nek7) | |
| CO2022017622A2 (es) | Inhibidores de quinasa nek7 | |
| DOP2022000124A (es) | Derivados de pirazolilo útiles como agentes anticancerígenos | |
| CO2022019131A2 (es) | Inhibidores de la quinasa nek7 | |
| MX2021008358A (es) | Lipidos para la administracion de agentes activos en nanoparticulas lipidicas. | |
| CO2019011762A2 (es) | Compuestos que inhiben la proteína mcl-1 | |
| CL2024001466A1 (es) | Inhibidores de lisina acetiltransferasa 6a (kat6a) y usos de los mismos | |
| PY1996328A (es) | Compuestos de azalactam como inhibidores de hpk1 | |
| MX388781B (es) | Compuestos de quinazolina sustituido y su uso como inhibidores de proteínas kras, hras y/o nras mutantes g12c. | |
| CO2024015820A2 (es) | Compuestos de heteroarilo para el tratamiento del dolor | |
| MX2022005732A (es) | Derivado de amida y metodo de preparacion para el mismo y uso del mismo en medicina. | |
| MX2024013019A (es) | Compuestos de heteroarilo para el tratamiento del dolor | |
| MX2025007218A (es) | Moduladores del inflamasoma nlrp3 y productos y metodos relacionados | |
| UY39625A (es) | Derivados tricíclicos útiles como inhibidores de parp7 | |
| CL2020003380A1 (es) | Compuestos que aumentan la actividad del proteosoma. | |
| MX2024010321A (es) | Inhibidores de la quinasa tipo polo 4 (plk4), composiciones farmaceuticas, metodos de preparacion y usos de los mismos | |
| UY28979A1 (es) | Derivados de hidrocloruros de 3-carboxamida, composiciones farmacéuticas que los contienen, procedimiento de preparación y su uso, útiles como inhibidores selectivos de gsk3 | |
| PE20210550A1 (es) | Compuestos de 4-metildihidropirimidinona y su uso farmaceutico | |
| CO2026000093A2 (es) | Composiciones farmacéuticas para inhibidores de la cinasa nek7 | |
| MX2021009194A (es) | Composiciones insecticidas resistentes a la degradación del ingrediente activo y proceso para la preparación de estas. | |
| MX2023012958A (es) | Compuestos y metodos anticonceptivos. | |
| CO2023012903A2 (es) | Derivados de pirimidina útiles como inhibidores de la proteína cinasa de repetición 2 rica en leucina (lrrk2) | |
| CR20240216A (es) | Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno | |
| AR124430A1 (es) | Inhibidores de arginasa y métodos de uso de ellos | |
| AR124698A1 (es) | Derivados tricíclicos útiles como inhibidores de parp7 |